Sobi's Olezarsen Cuts Acute Pancreatitis Risk by 85% in Severe Hypertriglyceridemia Trials

Event summary

  • Sobi's olezarsen reduced acute pancreatitis risk by 85% and triglycerides by 66% in severe hypertriglyceridemia patients after six months.
  • The analysis included 455 patients with baseline triglycerides ≥880 mg/dL from the CORE and CORE2 Phase 3 trials.
  • European Medicines Agency validated an indication extension application for olezarsen in March 2026; U.S. FDA accepted a supplemental New Drug Application for Priority Review in February 2026.
  • Olezarsen also reduced remnant cholesterol by 64% (80 mg dose) and 53% (50 mg dose), and non-HDL-C by 35% and 27%, respectively.

The big picture

Sobi's olezarsen demonstrates significant efficacy in reducing acute pancreatitis risk and triglyceride levels in severe hypertriglyceridemia, addressing a growing healthcare burden with increasing global incidence. The drug's potential approvals in the U.S. and Europe could position it as a key player in managing this rare disease, leveraging Sobi's expertise in breakthrough innovations for rare diseases. With approximately 2 million people living with severe hypertriglyceridemia in the EU5, the market opportunity is substantial.

What we're watching

Regulatory Approvals
Whether the U.S. FDA will approve the supplemental New Drug Application for olezarsen by the June 30, 2026 target date.
Market Expansion
The pace at which Sobi can commercialize olezarsen in ex-U.S. geographies, excluding Canada and China, under its license agreement with Ionis Pharmaceuticals.
Clinical Impact
How the 85% reduction in acute pancreatitis risk will influence adoption rates among patients with severe hypertriglyceridemia.